YI: יעד חציוני של אנליסטים 111 Inc

111, Inc. is developing China's leading digital healthcare hub, integrating remote diagnostics with pharmaceutical sales to optimize distribution. The business relies on large-scale logistics and network effects, which, under strict Chinese regulatory oversight, limit the entry of new players. The current metric stands at 11.99, while this chart of the company's market valuation is supplemented by data on IT architect hiring and the stability of the technical core.

To assess the fundamental value of YI, investors must compare the market price with the average target price calculations from leading investment banks. The analysts' consensus forecast aggregates professional business valuations, which is particularly critical for 111, Inc. given the stringent regulation of healthcare in the PRC and the presence of powerful network effects in pharmaceutical logistics.